SCHEMBL2272372

SCHEMBL2272372

O=C(NC1CCC(OC(=O)c2ccccc2)C1)c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.55
NPC1 O15118 2/20 0.53
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
RAB9A P51151 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
CHRNA7 P36544 2/20 0.52
HTR3E A5X5Y0 1/20 0.50
HTR3B O95264 1/20 0.50
HTR3A P46098 1/20 0.50
HTR3D Q70Z44 1/20 0.50
HTR3C Q8WXA8 1/20 0.50
GRM5 P41594 1/20 0.49
APOBEC3A P31941 1/20 0.49
APOBEC3G Q9HC16 1/20 0.49
CARM1 Q86X55 1/20 0.47
PRMT6 Q96LA8 1/20 0.47
SMYD3 Q9H7B4 1/20 0.47
LMNA P02545 1/20 0.46
TDP1 Q9NUW8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17627163 0.82 NPC1 (0.68) NPC1MEN1KMT2ARAB9ASMN1; SMN2
SCHEMBL4453290 0.79 MEN1 (0.69) EPHX2MEN1KMT2ACHRNA7HTR3E
SCHEMBL1786140 0.79 MEN1 (0.69) EPHX2MEN1KMT2ACHRNA7HTR3E
SCHEMBL2230140 0.79 NPC1 (0.79) NPC1MEN1KMT2ARAB9ASMN1; SMN2
SCHEMBL124395 0.79 NPC1 (0.79) NPC1MEN1KMT2ARAB9ASMN1; SMN2
SCHEMBL23573476 0.78 NPC1 (0.62) NPC1MEN1KMT2ARAB9ASMN1; SMN2
SCHEMBL23573218 0.78 NPC1 (0.62) NPC1MEN1KMT2ARAB9ASMN1; SMN2
Bicarbonate SCHEMBL11025569 0.77 NPC1 (0.76) NPC1MEN1KMT2ARAB9ASMN1; SMN2
Hydrochloric Acid SCHEMBL27945424 0.77 NPC1 (0.76) NPC1MEN1KMT2ARAB9ASMN1; SMN2
SCHEMBL6939679 0.76 CHRNA7 (0.60) EPHX2MEN1KMT2ACHRNA7HTR3E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101094829-B novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO.,LTD. (JP) 2012-02-08 CN disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
CN-101094829-A Novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO LTD (JP) 2007-12-26 CN disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 EPHX2 3045/4885NPC1 4836/4885MEN1 3105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.